Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **alpha-amylase starch-binding domain** (SBD) is a non-catalytic protein domain found in association with alpha-amylases, a class of enzymes that catalyze the hydrolysis of α-1,4-glucosidic linkages in starch and related polysaccharides. The SBD is responsible for binding to insoluble starch and raw starch granules, thereby increasing the local substrate concentration near the catalytic site and enhancing enzymatic efficiency toward complex starch substrates[1][3][9]. SBDs are commonly present as C-terminal domains in alpha-amylases, often consisting of one or more tandem modules, with notable diversity in their architecture (such as five identical repeats in *Lactobacillus amylovorus* alpha-amylase)[1][3][5][8]. These domains are classified within several carbohydrate-binding module (CBM) families (notably CBM20, CBM21, CBM25, CBM26, CBM34, CBM41, CBM45)[3]. SBDs do not possess catalytic activity themselves but play a key role in substrate recognition and enzyme–substrate interaction. While the presence of SBD is a critical structural and functional feature for enzymes acting on insoluble starch, the domain itself is not considered a distinct therapeutic target and does not have direct interacting drugs or involvement in human disease pathophysiology[1][9]. Further clarification: - The entity “Alpha-amylase starch-binding domains” does not refer to a single protein, gene, or standalone therapeutic target, but rather to a functional carbohydrate-binding module present in several amylolytic enzymes[3][9]. - SBDs play a biological role by enabling enzymes to bind and efficiently hydrolyze raw starch, and are important for biotechnological and industrial applications rather than as a direct human disease target[5][9]. - The family comprises diverse CBM subclasses, most frequently associated with glycoside hydrolase family 13[3][4]. If a specific alpha-amylase enzyme with clinical, pharmaceutical, or disease relevance was intended, please provide its full name or gene designation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-amylase starch-binding domain (SBD).